We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Seagen, Inc., a biotechnology company, focuses on developing & commercializing therapies targeted for the treatment of cancer. Adcetris, a lead FDA approved marketed product at Seagen, is used for treating Hodgkin lymphoma, certain T-cell lymphomas, other cancers in the U.S., Europe & several countries. Seagen has an agreement with Takeda Pharmaceutical Company Ltd. for the further development and commercialization of Adcetris. Seagen retains all rights to sell Adcetris in the U.S. and Canada, while Takeda has commercial rights to the drug in the rest of the world. The FDA granted approvals to Seagen's several drugs named Padcev, for treating advanced/metastatic urothelial cancer; Tukysa and Tivdak for treating adult patients with locally advanced/metastatic HER2-positive breast cancer and for the treatment of recurrent/metastatic cervical cancer in adult patients respectively. The company also has license agreements with partners like Merck, Roche, GlaxoSmithKline, Astellas, AbbVie, Bristol-Myers and Genmab.
- Recent SGEN Stock Price: $177.73
- Yearly Gain for SGEN stock: 10.32%
- Market Cap for SGEN stock: $32.72B
- P/E Ratio for SGEN stock: -47.51
Will SGEN's stock price go up? Is there an accurate SGEN stock forecast available?
TipRanks.com reports that Seagen currently has 11 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $170.20. The target pricing ranges from a high SGEN forecast of $208.00 down to a low forecast of $136.00. Seagen (SGEN)’s last closing stock price was $177.73 which would put the average price target at -4.24% upside.
In addition, TradingView issued a Buy rating for SGEN stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on SGEN stock.
Other analysts covering SGEN include:
- Matthew Harrison of Morgan Stanley issued a Buy rating with the price target of $ 173 on 1 week ago
- Jay Olson of Oppenheimer issued a Buy rating with the price target of $ 208 on 1 week ago
- Reni Benjamin of JMP Securities issued a Buy rating with the price target of $ 157 on 2 weeks ago
- Andrew Berens of SVB Securities issued a Buy rating with the price target of $ 159 on 3 weeks ago
If you are wondering if SGEN is a good stock to buy, here are 3rd party ratings for SGEN stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Top 39% (98 out of 251)
What is the sentiment on the street regarding Seagen? (Current ratings compiled by TipRanks.com)
- News Sentiment for SGEN stock: Very Bullish
- Blogger Consensus for SGEN stock: Bullish
- Media Buzz for SGEN stock: Medium
- Insider Signal for SGEN stock: Positive
- Investor Sentiment for SGEN stock: Very Positive
- Hedge Fund signal for SGEN stock: Positive
The stock market is extremely volatile, and you need to do your own research on SGEN stock including scouring the social networks like SGEN StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for SGEN stock chart >>
Summary: Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina.
- Recent CMRX Stock Price: $2.1
- Yearly Gain for CMRX stock: -73.39%
- Market Cap for CMRX stock: $183.62M
- P/E Ratio for CMRX stock: -1.775
Will CMRX's stock price go up? Is there an accurate CMRX stock forecast available?
TipRanks.com reports that Chimerix currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $8.00. The target pricing ranges from a high CMRX forecast of $11.00 down to a low forecast of $5.00. Chimerix (CMRX)’s last closing stock price was $2.1 which would put the average price target at 280.95% upside.
In addition, TradingView issued a Neutral rating for CMRX stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on CMRX stock.
Other analysts covering CMRX include:
- Soumit Roy of JonesTrading issued a Buy rating with the price target of $ 5 on 1 month ago
- Joseph Thome of Cowen & Co. issued a Buy rating with the price target of n/a on 1 month ago
- Maury Raycroft of Jefferies issued a Buy rating with the price target of $ 22 on 6 months ago
- David Nierengarten of Wedbush issued a Buy rating with the price target of $ 14 on 7 months ago
If you are wondering if CMRX is a good stock to buy, here are 3rd party ratings for CMRX stock:
- TipRanks.com: Strong Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 34% (166 out of 251)
What is the sentiment on the street regarding Chimerix? (Current ratings compiled by TipRanks.com)
- News Sentiment for CMRX stock: Very Bullish
- Blogger Consensus for CMRX stock: Bullish
- Media Buzz for CMRX stock: High
- Insider Signal for CMRX stock: Positive
- Investor Sentiment for CMRX stock: Very Positive
- Hedge Fund signal for CMRX stock: Neutral
The stock market is extremely volatile, and you need to do your own research on CMRX stock including scouring the social networks like CMRX StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for CMRX stock chart >>
Summary: Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products primarily in the United States. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. Precision BioSciences Inc. is based in Durham, North Carolina.
- Recent DTIL Stock Price: $1.77
- Yearly Gain for DTIL stock: -88.06%
- Market Cap for DTIL stock: $174.14M
- P/E Ratio for DTIL stock: -2.214
Will DTIL's stock price go up? Is there an accurate DTIL stock forecast available?
TipRanks.com reports that Precision BioSciences currently has 6 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $11.20. The target pricing ranges from a high DTIL forecast of $20.00 down to a low forecast of $7.00. Precision BioSciences (DTIL)’s last closing stock price was $1.77 which would put the average price target at 532.77% upside.
In addition, TradingView issued a Buy rating for DTIL stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on DTIL stock.
Other analysts covering DTIL include:
- Justin Zelin of BTIG issued a Buy rating with the price target of $ 8 on 6 days ago
- Raju Prasad of William Blair issued a Hold rating with the price target of n/a on 6 days ago
- Benjamin Burnett of Stifel Nicolaus issued a Buy rating with the price target of $ 11 on 6 days ago
- Kostas Biliouris of BMO Capital issued a Buy rating with the price target of $ 7 on 1 week ago
If you are wondering if DTIL is a good stock to buy, here are 3rd party ratings for DTIL stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Buy, Top 39% (98 out of 251)
What is the sentiment on the street regarding Precision BioSciences? (Current ratings compiled by TipRanks.com)
- News Sentiment for DTIL stock: Very Bullish
- Blogger Consensus for DTIL stock: Bullish
- Media Buzz for DTIL stock: High
- Insider Signal for DTIL stock: Positive
- Investor Sentiment for DTIL stock: Very Positive
- Hedge Fund signal for DTIL stock: Neutral
The stock market is extremely volatile, and you need to do your own research on DTIL stock including scouring the social networks like DTIL StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for DTIL stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================